Key points from article :
Juvenescence has announced an equity investment of up to $6.5 million in BYOMass Inc., a Massachusetts-based biotech company focused on addressing age-related diseases by targeting metabolic control mechanisms. The collaboration between the two companies aims to accelerate the development of BYOMass's innovative therapeutic programs, which hold promise for tackling the significant healthcare challenges posed by chronic diseases associated with ageing.
In addition to the investment, BYOMass CEO Dr. Margaret Jackson has joined Juvenescence as Vice President and Head of Preclinical Research and Development. With nearly two decades of experience in drug discovery, including leadership roles at Pfizer, Dr. Jackson brings expertise in advancing treatments from early discovery to clinical trials. Her dual role is expected to strengthen both companies' efforts to develop life-changing therapies.
Juvenescence CEO Dr. Gregory Bailey emphasized the potential impact of BYOMass's work on reducing the burden of chronic diseases on healthcare systems and economies. Dr. Jackson expressed her enthusiasm for contributing to Juvenescence’s mission of promoting healthier, longer lives and for leveraging Juvenescence's ecosystem to advance BYOMass's programs. This partnership represents a significant step forward in addressing the challenges of ageing and chronic disease through innovative science.
